Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Shop allSign In
Sign In

Rybelsus Regulatory Status: US, EU, Canada, and UK Approvals Explained

By
Terry Dubrow, MD

Medically reviewed by Terry Dubrow, MD

Founder and Chief Medical Officer · Board certified in obesity medicine

Published Updated
6 linked public sourcesEditorial, sourcing, and corrections policy

HealthRX.com

Rybelsus is FDA approved for type 2 diabetes and heart risk

Print or save as PDF

Key numbers

  • 12.0%Share of SOUL participants on oral semaglutide who had cardiovascular death, non-fatal heart attack or non-fatal strokeSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 3 mgStarting dose of oral semaglutide taken for the first 30 days, which the label says is not effective for blood sugar controlSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1 in 10,000Upper estimate of how often EMA says NAION, a rare vision side effect, can occur on semaglutide medicines including RybelsusSource: ema.europa.eu, as cited Nov 7, 2026

See the public record for Semaglutide

At a glance

  • Drug / Rybelsus, oral semaglutide tablets (3, 7 and 14 mg)
  • Drug class / GLP-1 receptor agonist
  • US approval / September 20, 2019, NDA 213051 [1]
  • US indications / Blood sugar control in type 2 diabetes; cardiovascular risk reduction in high-risk type 2 diabetes [2]
  • Dosing / 3 mg for 30 days, then 7 mg, then 7 or 14 mg from day 61 [2]
  • EMA action / June 6, 2025: NAION recommended as a very rare side effect [3]

What the FDA approved Rybelsus for

Rybelsus was approved on September 20, 2019 under NDA 213051 as oral semaglutide tablets; the product now comes in 3 mg, 7 mg and 14 mg strengths [1]. The label in effect from January 30, 2026 lists two uses, shared with Ozempic tablets: improving glycemic control in adults with type 2 diabetes alongside diet and exercise, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them [2]. The cardiovascular use was added in a labeling supplement dated October 17, 2025 [1].

That second indication rests on SOUL, which randomized 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both to oral semaglutide up to 14 mg daily or placebo. The composite of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 12.0% versus 13.8% over a median 49.5 months (HR 0.86, 95% CI 0.77 to 0.96) [5].

The label says the 3 mg starting dose taken for the first 30 days is not effective for glycemic control; the dose then goes to 7 mg for days 31 to 60, and to 7 mg or 14 mg from day 61 [2].

What Rybelsus is not approved for

Rybelsus carries no weight-loss indication [2]. Semaglutide's weight indications belong to Wegovy: the injection was approved June 4, 2021, and Wegovy tablets (1.5, 4, 9 and 25 mg) on December 22, 2025 [6][4]. The label also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis [2].

Europe, Canada and the UK

On June 6, 2025, EMA's safety committee recommended that the product information for semaglutide medicines, including Rybelsus, list NAION (non-arteritic anterior ischemic optic neuropathy) as a very rare side effect, meaning up to 1 in 10,000 people [3]. Large epidemiological studies in adults with type 2 diabetes suggested about a two-fold relative increase in risk, roughly one extra case per 10,000 person-years, and the committee advised stopping treatment if NAION is confirmed [3]. That recommendation was sent to EMA's committee for human medicines, which adopts the agency's opinion [3].

The current US Rybelsus label (January 30, 2026) does not mention NAION; it only advises monitoring of people with a history of diabetic retinopathy [2]. Approval dates, indication wording and reimbursement status for the EU, Canada and the UK are not covered here. The prescribing information described above is the US label [2].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the label, what strength is the starting dose taken for the first 30 days?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Rybelsus outside the United States: decisions by regulator, 2020 to 2025

4 of 4 events shown

  1. ApprovalCanada

    Health Canada authorises Rybelsus

    Notice of Compliance issued to Novo Nordisk Canada Inc for a new drug submission.

    Source: Health Canada Notice of Compliance 23396

  2. ApprovalEuropean Union

    Rybelsus authorised in the European Union

    Current EU indication: Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in combination with other ...

    Source: European Medicines Agency, Rybelsus

  3. ApprovalJapan

    Rybelsus approved in Japan

    Drugs with a new route of administration indicated for the treatment of type 2 diabetes mellitus.

    Source: PMDA list of approved products

  4. ApprovalCanada

    Rybelsus in Canada: new indication : To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial

    New indication : To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.

    Source: Health Canada Notice of Compliance 36662

Events checked against their sources Nov 13, 2026.

Frequently asked questions

Is Rybelsus FDA approved?
Yes. It was approved on September 20, 2019 under NDA 213051 as oral semaglutide tablets for adults with type 2 diabetes, and it now comes in 3 mg, 7 mg and 14 mg strengths [1][2].
Is Rybelsus approved for weight loss?
No. Rybelsus has no weight-loss indication [2]. Semaglutide's weight indications belong to Wegovy, whose injection was approved June 4, 2021 and whose 1.5, 4, 9 and 25 mg tablets were approved on December 22, 2025 [6][4].
Does Rybelsus have a cardiovascular indication?
Yes. A labeling supplement dated October 17, 2025 added reducing major adverse cardiovascular events in adults with type 2 diabetes at high risk [1][2]. In SOUL, the composite occurred in 12.0% on oral semaglutide versus 13.8% on placebo (HR 0.86, 0.77 to 0.96) [5].
What did EMA conclude about Rybelsus and vision?
On June 6, 2025 EMA's safety committee recommended listing NAION as a very rare side effect of semaglutide medicines, up to 1 in 10,000 people, and advised stopping treatment if NAION is confirmed [3].
How do the Rybelsus and Ozempic tablet doses compare?
They are different products with different strengths. Rybelsus comes as 3, 7 and 14 mg tablets; Ozempic tablets come as 1.5, 4 and 9 mg. The label states the two are not substitutable on a milligram-for-milligram basis [2].

References

Show all 6 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  3. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA).
  4. Drugs@FDA: FDA-Approved Drugs.
  5. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012.
  6. Drugs@FDA: FDA-Approved Drugs.
Evidence overview for Rybelsus Regulatory Status: US, EU, Canada, and UK Approvals Explained